Targeting TRAIL death receptors

被引：42

作者：

Oldenhuis, C. N. A. M. ^{[1
]}

Stegehuis, J. H. ^{[1
]}

Walenkamp, A. M. E. ^{[1
]}

de Jong, S. ^{[1
]}

de Vries, E. G. E. ^{[1
]}

机构：

[1] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands

来源：

CURRENT OPINION IN PHARMACOLOGY | 2008年 / 8卷 / 04期

关键词：

D O I：

10.1016/j.coph.2008.06.011

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The natural occurring tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induces apoptosis following binding to the two TRAIL death receptors (DRs). Its recombinant form and monoclonal antibodies against the TRAIL DRs induce cell death in a wide variety of tumor cell lines and xenografts without causing toxicity to normal cells and are therefore potential attractive anticancer agents. These agents are currently in early clinical development. The phase 1 and 2 studies showed until now limited toxicity and tumor responses have been observed. Ongoing studies focus especially on combination of these agents with other targeted therapies or cytotoxic therapies. In this review, we summarize current knowledge on these agents and highlight their potential role in the intrinsically chemotherapy-resistant glioblastomas. In addition, we discuss the mechanisms to sensitize tumors cells to rhTRAIL by combination with the proteasome inhibitor bortezomib.

引用

页码：433 / 439

页数：7

共 32 条

[1] TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8 [J].

Belyanskaya, Larisa L. ;

Ziogas, Algirdas ;

Ns-Donaldson, Sally Hopki ;

Kurtz, Stefanie ;

Simon, Hans-Uwe ;

Stahel, Rolf ;

Zangemeister-Wittke, Uwe .

LUNG CANCER, 2008, 60 (03) :355-365

[2] Targeting TRAIL agonistic receptors for cancer therapy [J].

Carlo-Stella, Carmelo ;

Lavazza, Cristiana ;

Locatelli, Alberta ;

Vigano, Lucia ;

Gianni, Alessandro M. ;

Gianni, Luca .

CLINICAL CANCER RESEARCH, 2007, 13 (08) :2313-2317

[3] The clinical trail of TRAIL [J].

Duiker, E. W. ;

Mom, C. H. ;

de Jong, S. ;

Willemse, P. H. B. ;

Gietema, J. A. ;

van der Zee, A. G. J. ;

de Vries, E. G. E. .

EUROPEAN JOURNAL OF CANCER, 2006, 42 (14) :2233-2240

[4] TRAU-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis [J].

Finnberg, Niklas ;

Klein-Szanto, Andres J. P. ;

El-Deiry, Wafik S. .

JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (01) :111-123

[5] Modulation of TRAIL-induced apoptosis by HDAC inhibitors [J].

Fulda, Simone .

CURRENT CANCER DRUG TARGETS, 2008, 8 (02) :132-140

[6] Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer [J].

Greco, F. Anthony ;

Bonomi, Philip ;

Crawford, Jeffrey ;

Kelly, Karen ;

Oh, Yun ;

Halpern, Wendy ;

Lo, Larry ;

Gallant, Gilles ;

Klein, Jerry .

LUNG CANCER, 2008, 61 (01) :82-90

[7] TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development [J].

Grosse-Wilde, Anne ;

Voloshanenko, Oksana ;

Bailey, S. Lawrence ;

Longton, Gary M. ;

Schaefer, Uta ;

Csernok, Andreea I. ;

Schuetz, Guenter ;

Greiner, Erich F. ;

Kemp, Christopher J. ;

Walczak, Henning .

JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (01) :100-110

[8]

Hao CH, 2001, CANCER RES, V61, P1162

[9] TRAIL limits excessive host immune responses in bacterial meningitis [J].

Hoffmann, Olaf ;

Priller, Josef ;

Prozorovski, Timour ;

Schulze-Topphoff, Ulf ;

Baeva, Nevena ;

Lunemann, Jan D. ;

Aktas, Orhan ;

Mahrhofer, Cordula ;

Stricker, Sarah ;

Zipp, Frauke ;

Weber, Joerg R. .

JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (07) :2004-2013

[10] A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL [J].

Hymowitz, SG ;

O'Connell, MP ;

Ultsch, MH ;

Hurst, A ;

Totpal, K ;

Ashkenazi, A ;

de Vos, AM ;

Kelley, RF .

BIOCHEMISTRY, 2000, 39 (04) :633-640

← 1 2 3 4 →